Proffered Paper - NETs

LINK to Proffered Paper - NETs

LINK to STREAM (needs an ESMO registration)

1156O - Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)

The abstract concludes: Surufatinib significantly improved the PFS in Pts with progressive, well-differentiated advanced pNETs. The safety profile was manageable and consistent with observations in prior studies. Surufatinib represents a promising treatment option in the armamentarium against pNETs.

Read also ESMO's Daily Reporter News: 

Surufatinib is a Potential New Option in Advanced Pancreatic NETs


1160O - An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis

The abstract concludes: This IA suggests that 177Lu-satoreotide tetraxetan has an acceptable safety profile in patients with NET using a lower administered activity per cycle than in earlier studies with this agent or current protocols using SSTR2 agonists. Promising efficacy results encourage the pursuit of its development in this indication.


1157O - A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)

The abstract concludes: D+T combination showed modest activity in this heavily pretreated population. In high grade NENs, D+T reached the primary endpoint of increasing OS rate and deserves further evaluation. Objective radiological responses were infrequent. No new safety concerns have been observed in this large population of advanced NENs.


1913O - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

The abstract concludes: Pralsetinib demonstrated potent and durable clinical activity in RET+ MTC regardless of prior treatment with approved multikinase inhibitors or RET-mutation and was well tolerated.